Drug Interactions between isocarboxazid and ragweed pollen allergen extract
This report displays the potential drug interactions for the following 2 drugs:
- isocarboxazid
- ragweed pollen allergen extract
Interactions between your drugs
isocarboxazid ragweed pollen allergen extract
Applies to: isocarboxazid and ragweed pollen allergen extract
MONITOR: Monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), catechol-O-methyltransferase (COMT) inhibitors, thyroid hormone, antihistamines, cardiac glycosides (e.g. digoxin) and diuretics may potentiate the response to epinephrine, including fatal consequences, in the treatment of serious systemic reactions that may occur during immunotherapy with allergenic extracts. Vasoconstricting and hypertensive effects may be potentiated by MAOIs, tricyclic antidepressants, and COMT inhibitors. Arrhythmogenic effects may be potentiated by thyroid hormones, antihistamines, cardiac glycosides and diuretics.
MANAGEMENT: Immunotherapy with allergenic extracts may not be appropriate in patients receiving MAOIs, tricyclic antidepressants, COMT inhibitors, thyroid hormone, antihistamines and cardiac glycosides as these patients may experience an exaggerated response to the usual doses of epinephrine required to reverse a systemic reaction.
References (6)
- (2014) "Product Information. Grastek (timothy grass pollen allergen extract)." Merck & Co., Inc
- (2014) "Product Information. Ragwitek (ragweed pollen allergen extract)." Merck & Co., Inc
- (2014) "Product Information. Oralair (mixed grass pollens allergen extract)." Greer Laboratories Inc
- Cerner Multum, Inc. (2015) "Canadian Product Information."
- (2023) "Product Information. Palforzia (peanut allergen extract)." Aimmune Therapeutics
- (2022) "Product Information. Palforzia Level 1 (peanut allergen extract)." Aimmune Therapeutics UK Ltd
Drug and food interactions
isocarboxazid food
Applies to: isocarboxazid
CONTRAINDICATED: Foods that contain large amounts of tyramine may precipitate a hypertensive crisis in patients treated with monoamine oxidase inhibitors (MAOIs). The mechanism is inhibition of MAO-A, the enzyme responsible for metabolizing exogenous amines such as tyramine in the gut and preventing them from being absorbed intact. Once absorbed, tyramine is metabolized to octopamine, a substance that is believed to displace norepinephrine from storage granules.
GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of MAOIs. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.
MANAGEMENT: In general, patients treated with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should avoid consumption of products that contain large amounts of amines and protein foods in which aging or breakdown of protein is used to increase flavor. These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, salamis, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, sauerkraut, yogurt, papaya products, meat tenderizers, fava bean pods, protein extracts, yeast extracts, and dietary supplements. Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well. At least 14 days should elapse following discontinuation of MAOI therapy before these foods may be consumed. Specially designed reference materials and dietary consultation are recommended so that an appropriate and safe diet can be planned. Patients should be advised to promptly seek medical attention if they experience potential signs and symptoms of a hypertensive crisis such as severe headache, visual disturbances, difficulty thinking, stupor or coma, seizures, chest pain, unexplained nausea or vomiting, and stroke-like symptoms. Patients should also be counseled not to use MAOIs with alcohol, and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.
References (19)
- Pettinger WA, Soyangco FG, Oates JA (1968) "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther, 9, p. 442-7
- Goldberg LI (1964) "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA, 190, p. 456-62
- Nuessle WF, Norman FC, Miller HE (1965) "Pickled herring and tranylcypromine reaction." JAMA, 192, p. 142-3
- Sweet RA, Liebowitz MR, Holt CS, Heimberg RG (1991) "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol, 11, p. 331-2
- Walker JI, Davidson J, Zung WWK (1984) "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry, 45, p. 78-80
- Ban TA (1975) "Drug interactions with psychoactive drugs." Dis Nerv Syst, 36, p. 164-6
- Darcy PF, Griffin JP (1995) "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev, 14, p. 211-31
- Maxwell MB (1980) "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs, 3, p. 451-7
- (2001) "Product Information. Matulane (procarbazine)." Roche Laboratories
- De Vita VT, Hahn MA, Oliverio VT (1965) "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med, 120, p. 561-5
- Zetin M, Plon L, DeAntonio M (1987) "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry, 48, p. 499
- Domino EF, Selden EM (1984) "Red wine and reactions." J Clin Psychopharmacol, 4, p. 173-4
- Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D (1994) "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol, 14, p. 5-14
- Pohl R, Balon R, Berchou R (1988) "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry, 145, p. 651
- (2001) "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation
- (2001) "Product Information. Nardil (phenelzine)." Parke-Davis
- (2001) "Product Information. Marplan (isocarboxazid)." Roche Laboratories
- (2001) "Product Information. Zyvox (linezolid)." Pharmacia and Upjohn
- Martin TG (1996) "Serotonin syndrome." Ann Emerg Med, 28, p. 520-6
ragweed pollen allergen extract food
Applies to: ragweed pollen allergen extract
ADJUST DOSING INTERVAL: Since sublingual preparations of allergenic extracts are meant to be absorbed directly from tissues under the tongue into the blood stream, consuming food or beverage during or immediately after administration may reduce the systemic bioavailability of the medication.
MONITOR: Coadministration of allergenic extracts for allergy immunotherapy with alcohol may potentiate the risk of allergic reactions, including anaphylaxis. According to some studies, alcohol is an augmenting factor influencing immunological mechanisms that can induce more severe allergic reactions and is involved in up to 15% of cases of anaphylactic reactions. Proposed mechanisms include an increase in allergen absorption from altered permeability of the intestinal epithelial barrier, enhancing mast cell and basophil activation, and an increase in serum IgE concentrations. A causal relationship with all allergenic extracts has not been established.
MANAGEMENT: Food or beverage should not be taken with, or for at least 5 minutes after, the administration of sublingual allergenic extracts. Patients should also avoid swallowing for about 1 minute following placement of the allergen extract under the tongue. Caution is advised if allergenic extracts for immunotherapy are used concomitantly with alcohol. Some manufacturers of peanut allergen extract recommend alcohol not be consumed for 2 hours before, or 2 hours after taking peanut allergen extract and if alcohol use cannot be avoided, that withholding or decreasing peanut allergen dosage should be considered. Individual prescribing information should be consulted for further guidance and clinical monitoring may be considered.
References (8)
- (2014) "Product Information. Grastek (timothy grass pollen allergen extract)." Merck & Co., Inc
- (2014) "Product Information. Ragwitek (ragweed pollen allergen extract)." Merck & Co., Inc
- (2014) "Product Information. Oralair (mixed grass pollens allergen extract)." Greer Laboratories Inc
- Cerner Multum, Inc. (2015) "Canadian Product Information."
- (2023) "Product Information. Palforzia (peanut allergen extract)." Aimmune Therapeutics
- (2022) "Product Information. Palforzia Level 1 (peanut allergen extract)." Aimmune Therapeutics UK Ltd
- Munoz-Cano R, Pascal M, Araujo G, et al. (2023) Mechanisms, Cofactors, and Augmenting Factors Involved in Anaphylaxis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5623009/pdf/fimmu-08-01193.pdf
- (2023) "Product Information. Odactra (house dust mite allergen extract)." ALK-Abello Inc
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.